What is EGFR Lung Cancer? Understanding Biomarkers & Precision Medicine with Dr. Singhi | Pt 1/3

In the premiere of our EGFR Biomarker Series, we’re joined by Dr. Eric Singhi, a renowned thoracic oncologist at MD Anderson Cancer Center, to demystify the biology of an EGFR positive diagnosis.Lung cancer treatment has evolved into the "poster child" for precision medicine, but getting the right treatment starts with one critical step: Comprehensive Biomarker Testing. Dr. Singhi explains why this testing is the "gold standard" of care and uses the analogy of a "stuck switch" to describe how EGFR mutations drive uncontrolled cell growth. We also debunk common myths about who gets lung cancer and why your "street address" matters.In this episode, we discuss:The "Stuck Switch": A simple breakdown of EGFR biology.The Precision Medicine Revolution: Why EGFR requires a different approach than traditional chemo or immunotherapy.Tissue vs. Liquid Biopsy: How the "team effort" between blood and tissue samples ensures no mutation is missed.Finding Your "Street Address": Understanding the differences between Exon 19 deletions, L858R, and Exon 20 insertions.The Changing Outlook: Moving from a "months" mindset to living for years with targeted therapy.This episode is proudly sponsored by Johnson & Johnson.About Young Lung Cancer Initiative (YLCI)The YLCI is a 501(c)(3) nonprofit dedicated to the young-onset community. We provide support, research, and advocacy to ensure that no young person faces a lung cancer diagnosis alone.Disclaimer: This podcast is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.